Allele-Specific Silencing of Mutant Myh6 Transcripts in Mice Suppresses Hypertrophic Cardiomyopathy

被引:183
作者
Jiang, Jianming [1 ,3 ,4 ]
Wakimoto, Hiroko [1 ,2 ,3 ]
Seidman, J. G. [1 ]
Seidman, Christine E. [1 ,3 ,4 ]
机构
[1] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA
[2] Boston Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA
[4] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA
关键词
GENE-TRANSFER; MOUSE MODEL; PROGRESS; DISEASE;
D O I
10.1126/science.1236921
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Dominant mutations in sarcomere proteins such as the myosin heavy chains (MHC) are the leading genetic causes of human hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. We found that expression of the HCM-causing cardiac MHC gene (Myh6) R403Q mutation in mice can be selectively silenced by an RNA interference (RNAi) cassette delivered by an adeno-associated virus vector. RNAi-transduced MHC403/+ mice developed neither hypertrophy nor myocardial fibrosis, the pathologic manifestations of HCM, for at least 6 months. Because inhibition of HCM was achieved by only a 25% reduction in the levels of the mutant transcripts, we suggest that the variable clinical phenotype in HCM patients reflects allele-specific expression and that partial silencing of mutant transcripts may have therapeutic benefit.
引用
收藏
页码:111 / 114
页数:4
相关论文
共 27 条
[1]   Adeno-Associated Virus (AAV) Serotype 9 Provides Global Cardiac Gene Transfer Superior to AAV1, AAV6, AAV7, and AAV8 in the Mouse and Rat [J].
Bish, Lawrence T. ;
Morine, Kevin ;
Sleeper, Meg M. ;
Sanmiguel, Julio ;
Wu, Di ;
Gao, Guangping ;
Wilson, James M. ;
Sweeney, H. Lee .
HUMAN GENE THERAPY, 2008, 19 (12) :1359-1368
[2]  
Christodoulou DC, 2011, CURR PROTOC MOL BIOL, DOI [10.1002/0471142727.mb0412s94, DOI 10.1002/0471142727.MB0412S94]
[3]   Interfering with disease: a progress report on siRNA-based therapeutics [J].
de Fougerolles, Antonin ;
Vornlocher, Hans-Peter ;
Maraganore, John ;
Lieberman, Judy .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (06) :443-453
[4]   Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction [J].
Sammy Elmariah ;
Michael A. Fifer .
Current Treatment Options in Cardiovascular Medicine, 2012, 14 (6) :665-678
[5]   An abnormal Ca2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy [J].
Fatkin, D ;
McConnell, BK ;
Mudd, JO ;
Semsarian, C ;
Moskowitz, IGP ;
Schoen, FJ ;
Giewat, M ;
Seidman, CE ;
Seidman, JG .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (11) :1351-1359
[6]   New recombinant serotypes of AAV vectors [J].
Gao, GP ;
Vandenberghe, LH ;
Wilson, JM .
CURRENT GENE THERAPY, 2005, 5 (03) :285-297
[7]   A MOLECULAR-BASIS FOR FAMILIAL HYPERTROPHIC CARDIOMYOPATHY - A BETA-CARDIAC MYOSIN HEAVY-CHAIN GENE MISSENSE MUTATION [J].
GEISTERFERLOWRANCE, AAT ;
KASS, S ;
TANIGAWA, G ;
VOSBERG, HP ;
MCKENNA, W ;
SEIDMAN, CE ;
SEIDMAN, JG .
CELL, 1990, 62 (05) :999-1006
[8]   A mouse model of familial hypertrophic cardiomyopathy [J].
GeisterferLowrance, AAT ;
Christe, M ;
Conner, DA ;
Ingwall, JS ;
Schoen, FJ ;
Seidman, CE ;
Seidman, JG .
SCIENCE, 1996, 272 (5262) :731-734
[9]   Hypertrophic Cardiomyopathy in 2012 [J].
Ho, Carolyn Y. .
CIRCULATION, 2012, 125 (11) :1432-1438
[10]   Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy [J].
Ho, CY ;
Sweitzer, NK ;
McDonough, B ;
Maron, BJ ;
Casey, SA ;
Seidman, JG ;
Seidman, CE ;
Solomon, SD .
CIRCULATION, 2002, 105 (25) :2992-2997